Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): PMS-Dorzolamide-Timolol (02442426), Dorzolamide and Timolol Eye Drops BP (02489635). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.

DORZOLAMIDE HCL & TIMOLOL MALEATE

Form:

11 of 11 products shown

All products: Limited Use (codes 310, 393)

Other products in the same Health Canada class (S01ED) — coverage varies; not interchangeable

  • Betaxolol (Betoptic S): general benefit
  • Levobunolol (Betagan): general benefit
  • Timolol (Timoptic-XE): general benefit, Not a benefit
  • Brimonidine + timolol (Apo-Brimonidine-Timop): limited Use 310, 393
  • Brinzolamide + timolol (Azarga): limited Use 310, 393
  • Latanoprost + timolol (Xalacom): limited Use 310, 393

11 more in the class list below

Apo-Dorzo-Timop · DIN 02299615 · 2% & 0.5% · Oph Sol

Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 310, 393 required
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Dorzo-Timop · DIN 02299615 Manufacturer: Apotex Inc.; listing date 2011-12-15 Health Canada: Marketed since 2018-06-15 · brand APO-DORZO-TIMOP · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20 MG/ML, TIMOLOL (TIMOLOL MALEATE) 5 MG/ML · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Dorzo-Timop: Formulary list price $2.0951/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.0951 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78499 · Verify on the e-Formulary ↗ (DIN 02299615)

Source record
DIN 02299615: Apo-Dorzo-Timop Raw flags: sec12=Y, sec3=Y Item: 523600098; group id 624; item number 1591; lccId 00087; manufacturer id APX Source form: Oph Sol; strength: 2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.0951; ministry $2.0951 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02299615 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78499
Interchangeable products
Co Dorzotimolol · DIN 02404389 · $2.0951 Cosopt · DIN 02240113 · $2.0951 Dorzolamide-Timolol · DIN 02522020 · $2.0951 Jamp Dorzolamide-Timolol · DIN 02457539 · $2.0951 M-Dorzolamide-Timolol · DIN 02537796 · $2.0951 Med-Dorzolamide-Timolol · DIN 02437686 · $2.0951 Mint-Dorzolamide/Timolol · DIN 02443090 · $2.0951 Riva-Dorzolamide/Timolol · DIN 02441659 · $2.0951 Sandoz Dorzolamide/Timolol · DIN 02344351 · $2.0951
Shortage status: shortage reported ended 2026-04-30 (report last updated 2026-04-30); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02299615
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cosopt · DIN 02240113 · 2% & 0.5% · Oph Sol

Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 310, 393 required
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Savings card: RxHelp ONE lists Cosopt (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Cosopt · DIN 02240113 Manufacturer: Elvium Life Sciences; listing date 2000-01-17 Health Canada: Marketed since 2020-08-31 · brand COSOPT · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 5 MG/ML, DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20 MG/ML · company Elvium life sciences · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $2.0951 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63627 · Verify on the e-Formulary ↗ (DIN 02240113)

Source record
DIN 02240113: Cosopt Raw flags: sec12=Y, sec3=Y Item: 523600098; group id 624; item number 1591; lccId 00087; manufacturer id ELV Source form: Oph Sol; strength: 2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $9.8639; ministry $2.0951 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240113 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63627
Interchangeable products
Apo-Dorzo-Timop · DIN 02299615 · $2.0951 Co Dorzotimolol · DIN 02404389 · $2.0951 Dorzolamide-Timolol · DIN 02522020 · $2.0951 Jamp Dorzolamide-Timolol · DIN 02457539 · $2.0951 M-Dorzolamide-Timolol · DIN 02537796 · $2.0951 Med-Dorzolamide-Timolol · DIN 02437686 · $2.0951 Mint-Dorzolamide/Timolol · DIN 02443090 · $2.0951 Riva-Dorzolamide/Timolol · DIN 02441659 · $2.0951 Sandoz Dorzolamide/Timolol · DIN 02344351 · $2.0951
Shortage status: resolved shortage (ended 2025-07-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240113
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Dorzolamide-Timolol · DIN 02522020 · 2% & 0.5% · Oph Sol

Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 310, 393 required
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Dorzolamide-Timolol · DIN 02522020 Manufacturer: Jamp Pharma Corporation; listing date 2023-08-31 Health Canada: Marketed since 2023-06-12 · brand DORZOLAMIDE-TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20 MG/ML, TIMOLOL (TIMOLOL MALEATE) 5 MG/ML · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Dorzolamide-Timolol: Formulary list price $2.0951/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.0951 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101119 · Verify on the e-Formulary ↗ (DIN 02522020)

Source record
DIN 02522020: Dorzolamide-Timolol Raw flags: sec12=Y, sec3=Y Item: 523600098; group id 624; item number 1591; lccId 00087; manufacturer id JPC Source form: Oph Sol; strength: 2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.0951; ministry $2.0951 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02522020 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101119
Interchangeable products
Apo-Dorzo-Timop · DIN 02299615 · $2.0951 Co Dorzotimolol · DIN 02404389 · $2.0951 Cosopt · DIN 02240113 · $2.0951 Jamp Dorzolamide-Timolol · DIN 02457539 · $2.0951 M-Dorzolamide-Timolol · DIN 02537796 · $2.0951 Med-Dorzolamide-Timolol · DIN 02437686 · $2.0951 Mint-Dorzolamide/Timolol · DIN 02443090 · $2.0951 Riva-Dorzolamide/Timolol · DIN 02441659 · $2.0951 Sandoz Dorzolamide/Timolol · DIN 02344351 · $2.0951
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02522020
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Dorzolamide-Timolol · DIN 02537796 · 2% & 0.5% · Oph Sol

Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-19
StatusLimited Use — Reason for Use code 310, 393 required
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Dorzolamide-Timolol · DIN 02537796 Manufacturer: Mantra Pharma Inc.; listing date 2023-12-29 Health Canada: Marketed since 2023-11-13 · brand M-DORZOLAMIDE-TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20 MG/ML, TIMOLOL (TIMOLOL MALEATE) 5 MG/ML · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Dorzolamide-Timolol: Formulary list price $2.0951/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.0951 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102656 · Verify on the e-Formulary ↗ (DIN 02537796)

Source record
DIN 02537796: M-Dorzolamide-Timolol Raw flags: sec12=Y, sec3=Y Item: 523600098; group id 624; item number 1591; lccId 00087; manufacturer id MAT Source form: Oph Sol; strength: 2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.0951; ministry $2.0951 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02537796 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102656
Interchangeable products
Apo-Dorzo-Timop · DIN 02299615 · $2.0951 Co Dorzotimolol · DIN 02404389 · $2.0951 Cosopt · DIN 02240113 · $2.0951 Dorzolamide-Timolol · DIN 02522020 · $2.0951 Jamp Dorzolamide-Timolol · DIN 02457539 · $2.0951 Med-Dorzolamide-Timolol · DIN 02437686 · $2.0951 Mint-Dorzolamide/Timolol · DIN 02443090 · $2.0951 Riva-Dorzolamide/Timolol · DIN 02441659 · $2.0951 Sandoz Dorzolamide/Timolol · DIN 02344351 · $2.0951
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02537796
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Med-Dorzolamide-Timolol · DIN 02437686 · 2% & 0.5% · Oph Sol

Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 310, 393 required
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Med-Dorzolamide-Timolol · DIN 02437686 Manufacturer: Generic Medical Partners Inc.; listing date 2016-10-27 Health Canada: Marketed since 2016-05-17 · brand MED-DORZOLAMIDE-TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 5 MG/ML, DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20 MG/ML · company Generic medical partners inc · schedule Prescription
Check this DIN again · Health Canada product record

Med-Dorzolamide-Timolol: Formulary list price $2.0951/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.0951 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92207 · Verify on the e-Formulary ↗ (DIN 02437686)

Source record
DIN 02437686: Med-Dorzolamide-Timolol Raw flags: sec12=Y, sec3=Y Item: 523600098; group id 624; item number 1591; lccId 00087; manufacturer id GMP Source form: Oph Sol; strength: 2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.0951; ministry $2.0951 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02437686 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92207
Interchangeable products
Apo-Dorzo-Timop · DIN 02299615 · $2.0951 Co Dorzotimolol · DIN 02404389 · $2.0951 Cosopt · DIN 02240113 · $2.0951 Dorzolamide-Timolol · DIN 02522020 · $2.0951 Jamp Dorzolamide-Timolol · DIN 02457539 · $2.0951 M-Dorzolamide-Timolol · DIN 02537796 · $2.0951 Mint-Dorzolamide/Timolol · DIN 02443090 · $2.0951 Riva-Dorzolamide/Timolol · DIN 02441659 · $2.0951 Sandoz Dorzolamide/Timolol · DIN 02344351 · $2.0951
Shortage status: resolved shortage (ended 2020-02-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02437686
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Riva-Dorzolamide/Timolol · DIN 02441659 · 2% & 0.5% · Oph Sol

Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 310, 393 required
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Riva-Dorzolamide/Timolol · DIN 02441659 Manufacturer: Laboratoire Riva Inc.; listing date 2021-08-31 Health Canada: Marketed since 2015-07-22 · brand RIVA-DORZOLAMIDE/TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20 MG/ML, TIMOLOL (TIMOLOL MALEATE) 5 MG/ML · company Laboratoire riva inc. · schedule Prescription
Check this DIN again · Health Canada product record

Riva-Dorzolamide/Timolol: Formulary list price $2.0951/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.0951 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92604 · Verify on the e-Formulary ↗ (DIN 02441659)

Source record
DIN 02441659: Riva-Dorzolamide/Timolol Raw flags: sec12=Y, sec3=Y Item: 523600098; group id 624; item number 1591; lccId 00087; manufacturer id RIA Source form: Oph Sol; strength: 2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.0951; ministry $2.0951 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02441659 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92604
Interchangeable products
Apo-Dorzo-Timop · DIN 02299615 · $2.0951 Co Dorzotimolol · DIN 02404389 · $2.0951 Cosopt · DIN 02240113 · $2.0951 Dorzolamide-Timolol · DIN 02522020 · $2.0951 Jamp Dorzolamide-Timolol · DIN 02457539 · $2.0951 M-Dorzolamide-Timolol · DIN 02537796 · $2.0951 Med-Dorzolamide-Timolol · DIN 02437686 · $2.0951 Mint-Dorzolamide/Timolol · DIN 02443090 · $2.0951 Sandoz Dorzolamide/Timolol · DIN 02344351 · $2.0951
Shortage status: resolved shortage (ended 2020-01-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02441659
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Dorzolamide/Timolol · DIN 02344351 · 2% & 0.5% · Oph Sol

Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 310, 393 required
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Dorzolamide/Timolol · DIN 02344351 Manufacturer: Sandoz Canada Inc.; listing date 2014-07-30 Health Canada: Marketed since 2010-10-25 · brand SANDOZ DORZOLAMIDE/TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 5 MG/ML, DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20 MG/ML · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Dorzolamide/Timolol: Formulary list price $2.0951/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.0951 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82984 · Verify on the e-Formulary ↗ (DIN 02344351)

Source record
DIN 02344351: Sandoz Dorzolamide/Timolol Raw flags: sec12=Y, sec3=Y Item: 523600098; group id 624; item number 1591; lccId 00087; manufacturer id SDZ Source form: Oph Sol; strength: 2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.0951; ministry $2.0951 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02344351 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82984
Interchangeable products
Apo-Dorzo-Timop · DIN 02299615 · $2.0951 Co Dorzotimolol · DIN 02404389 · $2.0951 Cosopt · DIN 02240113 · $2.0951 Dorzolamide-Timolol · DIN 02522020 · $2.0951 Jamp Dorzolamide-Timolol · DIN 02457539 · $2.0951 M-Dorzolamide-Timolol · DIN 02537796 · $2.0951 Med-Dorzolamide-Timolol · DIN 02437686 · $2.0951 Mint-Dorzolamide/Timolol · DIN 02443090 · $2.0951 Riva-Dorzolamide/Timolol · DIN 02441659 · $2.0951
Shortage status: resolved shortage (ended 2026-08-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02344351
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Cosopt Preservative Free · DIN 02258692 · 2% & 0.5% · Oph Sol-0.2mL Pk

Limited Use — Reason for Use code 310, 393 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 310, 393 required
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
No interchangeable product listed in the Ontario extract
Cosopt Preservative Free · DIN 02258692 Manufacturer: Elvium Life Sciences; listing date 2010-04-23 Health Canada: Marketed since 2022-05-24 · brand COSOPT PRESERVATIVE-FREE · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20 MG/ML, TIMOLOL (TIMOLOL MALEATE) 5 MG/ML · company Elvium life sciences · schedule Prescription
Check this DIN again · Health Canada product record

Cosopt Preservative Free: Formulary list price $0.8930/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.8930 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74388 · Verify on the e-Formulary ↗ (DIN 02258692)

Source record
DIN 02258692: Cosopt Preservative Free Raw flags: sec12=Y, sec3=Y Item: 523600113; group id 624; item number 1592; lccId 00087; manufacturer id ELV Source form: Oph Sol-0.2mL Pk; strength: 2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.8930; ministry $0.8930 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02258692 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74388
Shortage status: resolved shortage (ended 2026-08-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02258692
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Dorzolamide-Timolol · DIN 02457539 · 2% & 0.5% · Oph Sol

Limited Use — Reason for Use code 310, 393 requiredDormant since 2025-07-31 · checked 2026-09-02 · What does dormant mean?
StatusLimited Use — Reason for Use code 310, 393 required
Write on scriptLU code 310, 393 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Dorzolamide-Timolol · DIN 02457539 Manufacturer: Jamp Pharma Corporation; listing date 2020-02-28 Health Canada: Dormant since 2025-07-31 · brand JAMP DORZOLAMIDE-TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20 MG/ML, TIMOLOL (TIMOLOL MALEATE) 5 MG/ML · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Dorzolamide-Timolol: Formulary list price $2.0951/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.0951 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94459 · Verify on the e-Formulary ↗ (DIN 02457539)

Source record
DIN 02457539: Jamp Dorzolamide-Timolol Raw flags: sec12=Y, sec3=Y Item: 523600098; group id 624; item number 1591; lccId 00087; manufacturer id JPC Source form: Oph Sol; strength: 2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.0951; ministry $2.0951 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02457539 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94459
Interchangeable products
Apo-Dorzo-Timop · DIN 02299615 · $2.0951 Co Dorzotimolol · DIN 02404389 · $2.0951 Cosopt · DIN 02240113 · $2.0951 Dorzolamide-Timolol · DIN 02522020 · $2.0951 M-Dorzolamide-Timolol · DIN 02537796 · $2.0951 Med-Dorzolamide-Timolol · DIN 02437686 · $2.0951 Mint-Dorzolamide/Timolol · DIN 02443090 · $2.0951 Riva-Dorzolamide/Timolol · DIN 02441659 · $2.0951 Sandoz Dorzolamide/Timolol · DIN 02344351 · $2.0951
Shortage status: resolved shortage (ended 2023-07-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02457539
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-07-31 — choose a marketed DIN from the same-category list.

Co Dorzotimolol · DIN 02404389 · 2% & 0.5% · Oph Sol

Limited Use — Reason for Use code 310, 393 required; Health Canada lists this DIN as Cancelled post market since 2019-03-12 — choose a marketed DIN from the same-category list.Discontinued 2019-03-12 · checked 2026-09-02
StatusLimited Use — Reason for Use code 310, 393 required; Health Canada lists this DIN as Cancelled post market since 2019-03-12 — choose a marketed DIN from the same-category list.
Write on scriptLU code 310, 393 (patient must meet the criteria below); Health Canada lists this DIN as Cancelled post market since 2019-03-12 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Co Dorzotimolol · DIN 02404389 Manufacturer: Cobalt Pharmaceuticals Company; listing date 2014-01-03 Health Canada: Cancelled post market since 2019-03-12 · brand ACT DORZOTIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20 MG/ML, TIMOLOL (TIMOLOL MALEATE) 5 MG/ML · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Co Dorzotimolol: Formulary list price $2.0951/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.0951 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88915 · Verify on the e-Formulary ↗ (DIN 02404389)

Source record
DIN 02404389: Co Dorzotimolol Raw flags: sec12=Y, sec3=Y Item: 523600098; group id 624; item number 1591; lccId 00087; manufacturer id COB Source form: Oph Sol; strength: 2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.0951; ministry $2.0951 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02404389 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88915
Interchangeable products
Apo-Dorzo-Timop · DIN 02299615 · $2.0951 Cosopt · DIN 02240113 · $2.0951 Dorzolamide-Timolol · DIN 02522020 · $2.0951 Jamp Dorzolamide-Timolol · DIN 02457539 · $2.0951 M-Dorzolamide-Timolol · DIN 02537796 · $2.0951 Med-Dorzolamide-Timolol · DIN 02437686 · $2.0951 Mint-Dorzolamide/Timolol · DIN 02443090 · $2.0951 Riva-Dorzolamide/Timolol · DIN 02441659 · $2.0951 Sandoz Dorzolamide/Timolol · DIN 02344351 · $2.0951
Shortage status: discontinued (2019-05-01, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02404389
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2019-03-12 — choose a marketed DIN from the same-category list.

Mint-Dorzolamide/Timolol · DIN 02443090 · 2% & 0.5% · Oph Sol

Limited Use — Reason for Use code 310, 393 required; Health Canada lists this DIN as Cancelled post market since 2019-05-23 — choose a marketed DIN from the same-category list.Discontinued 2019-05-23 · checked 2026-09-02
StatusLimited Use — Reason for Use code 310, 393 required; Health Canada lists this DIN as Cancelled post market since 2019-05-23 — choose a marketed DIN from the same-category list.
Write on scriptLU code 310, 393 (patient must meet the criteria below); Health Canada lists this DIN as Cancelled post market since 2019-05-23 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 310, 393
Reason for Use code 310 As second-line therapy for patients who do not have an adequate intraocular pressure lowering response to monotherapy with ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 393 For use as initial therapy in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Dorzolamide/Timolol · DIN 02443090 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2016-10-27 Health Canada: Cancelled post market since 2019-05-23 · brand MINT-DORZOLAMIDE/TIMOLOL · ATC S01ED51 TIMOLOL, COMBINATIONS, S01ED51 TIMOLOL, COMBINATIONS · form Solution · route Ophthalmic · ingredients TIMOLOL (TIMOLOL MALEATE) 5 MG/ML, DORZOLAMIDE (DORZOLAMIDE HYDROCHLORIDE) 20 MG/ML · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Dorzolamide/Timolol: Formulary list price $2.0951/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.0951 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92763 · Verify on the e-Formulary ↗ (DIN 02443090)

Source record
DIN 02443090: Mint-Dorzolamide/Timolol Raw flags: sec12=Y, sec3=Y Item: 523600098; group id 624; item number 1591; lccId 00087; manufacturer id MIN Source form: Oph Sol; strength: 2% & 0.5% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.0951; ministry $2.0951 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02443090 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92763
Interchangeable products
Apo-Dorzo-Timop · DIN 02299615 · $2.0951 Co Dorzotimolol · DIN 02404389 · $2.0951 Cosopt · DIN 02240113 · $2.0951 Dorzolamide-Timolol · DIN 02522020 · $2.0951 Jamp Dorzolamide-Timolol · DIN 02457539 · $2.0951 M-Dorzolamide-Timolol · DIN 02537796 · $2.0951 Med-Dorzolamide-Timolol · DIN 02437686 · $2.0951 Riva-Dorzolamide/Timolol · DIN 02441659 · $2.0951 Sandoz Dorzolamide/Timolol · DIN 02344351 · $2.0951
Shortage status: discontinued (2019-05-31, reported by MINT PHARMACEUTICALS INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443090
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2019-05-23 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE 52:36 Other Eye, Ear, Nose and Throat Agents

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

TIMOLOL MALEATE

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol

BRIMONIDINE TARTRATE & TIMOLOL MALEATE

· 3 products · Limited Use, codes 310, 393 · strengths: 0.2% & 0.5% · Oph Sol-10mL Pk

BRINZOLAMIDE & TIMOLOL MALEATE

· 1 products · Limited Use, codes 310, 393 · strengths: 1% & 0.5% · Oph Susp-5mL Pk

LATANOPROST & TIMOLOL MALEATE

· 9 products · Limited Use, codes 310, 393 · strengths: 50mcg/mL & 5mg/mL · Oph Sol-2.5mL Pk

TIMOLOL MALEATE & TRAVOPROST

· 4 products · Listed, not a benefit (1), Limited Use, codes 310, 393 (3) · strengths: 0.5% & 0.004% · Oph Sol, Oph Sol-5mL Pk

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

BRIMONIDINE

· 7 products · Limited Use, codes 171, 172, 387 · strengths: 0.15%, 0.2% · Oph Sol

BRINZOLAMIDE

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 1% · Oph Susp Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:36 and 20 more
Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS COSOPT® (dorzolamide hydrochloride and timolol maleate) and COSOPT® preservative-free (without benzalkonium chloride as the preservative) are indicated in the treatment of elevated intraocular pressure (IOP) in patients with: • ocular hypertension • open-angle glaucoma when concomitant therapy is appropriate. COSOPT preservative-free is indicated in patients who may be sensitive to a preservative, or for whom the use of a preservative-free formulation is otherwise advisable. For details please also refer to the 4 DOSAGE AND ADMINISTRATION section as well as to the 14 CLINICAL TRIALS section. 1.1 Pediatrics Pediatrics (<18 years of age): Safety and effectiveness in children have not been established. No data are available to Health Canada; therefore, an indication for pediatric use has not been authorized. 1.2 Geriatrics Geriatrics (>65 years of age): No overall differences in effectiveness or safety were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out (see 7.1.4 Geriatrics). https://pdf.hres.ca/dpd_pm/00073687.PDF PM date: OCT 25, 2016 Source product: COSOPT; DIN 02240113; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Apo-Dorzo-Timop · DIN 02299615 Shortage status: shortage reported ended 2026-04-30 (report last updated 2026-04-30); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02299615

Check this DIN again

Co Dorzotimolol · DIN 02404389 Shortage status: discontinued (2019-05-01, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02404389

Check this DIN again

Mint-Dorzolamide/Timolol · DIN 02443090 Shortage status: discontinued (2019-05-31, reported by MINT PHARMACEUTICALS INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02443090

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)